HOME >> BIOLOGY >> NEWS
Over the edge: New therapeutic strategy takes advantage of stressed cancer cells

A biochemical alteration that has long been viewed as an adverse aspect of tumor biology may turn out to be a deadly double-edged sword for the cancer cells themselves. Scientists have successfully exploited the oxidative stress common in cancer cells to preferentially kill malignant cells. This approach has the therapeutic advantage of selectively targeting cancer cells while exhibiting minimal toxicity in normal cells. The research is published in the September 2006 issue of the journal Cancer Cell, published by Cell Press.

Most cancer cells exhibit overproduction of reactive oxygen species (ROS), which is thought to provide favorable conditions for cancer cell growth, genetic instability, and survival. Dr. Peng Huang from the Department of Molecular Pathology at the University of Texas M.D. Anderson Cancer Center and colleagues hypothesized that increased ROS generation may also make cancer cells highly vulnerable to exogenous ROS-modulating agents that would not be toxic to normal cells with low ROS output.

The researchers examined the ability of a naturally occurring compound called -phenylethyl isothiocyanate (PEITC), which is known to modulate cellular antioxidant pathways, to push cancer cells to even higher ROS levels that result in cell death. Oncogenically transformed cells exhibited high basal ROS levels and were more sensitive to PEITC than nontransformed cells. PEITC interfered with a specific antioxidant system that the cancer cells relied on to maintain a ROS balance that was compatible with survival. Treatment with PEITC led to further ROS accumulation that caused massive death of cancer cells but no cytotoxicity in normal cells. Importantly, PEITC also significantly prolonged survival in an animal model of human cancer.

"Our study suggests that the intrinsic oxidative stress in cancer cells associated with oncogenic transformation provides a basis for developing therapeutic strategies to preferentially kill cancer cell
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
11-Sep-2006


Page: 1 2

Related biology news :

1. On the cutting edge: Carbon nanotube cutlery
2. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
3. From clinical cancer research: rethinking therapeutic cancer vaccine trials
4. Sensitivity to diverse range of chemotherapeutic drugs linked to common pathway
5. New therapeutic insight into duchenne muscular dystrophy
6. Small molecule derived from Rb2/p130 could act as cancer therapeutic
7. Sphingolipids with therapeutic ends
8. New therapeutic target for Alzheimers could lead to drugs without side effects
9. VBI research offers potential route to diabetes therapeutics
10. Quiet revolution may herald new RNA therapeutics
11. Scientists discover two-component lantibiotic with therapeutic potential

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2020)... ... 2020 , ... LabKey has released Sample Manager, sample ... processing within laboratories. , Built with input from a Product Advisory Council ... Sample Manager has been designed with an intuitive user interface providing a gateway ...
(Date:1/30/2020)... ... January 30, 2020 , ... Accelera Canada , a full-service firm ... market, is pleased to announce that the company has opened the doors of its ... in 2017. , “We are so thrilled to now have all our partners ...
(Date:1/29/2020)... ... January 29, 2020 , ... INDIGO Biosciences, ... testing solutions, has announced a record earnings year for 2019. With final numbers ... than a twenty percent increase in revenue and a thirty percent increase in ...
Breaking Biology News(10 mins):
(Date:2/11/2020)... ... February 11, 2020 , ... ... services in North America, today announced that the City of Fort Worth has ... biosolids management needs. Commencing in April of 2020, Synagro will assume operation of ...
(Date:2/3/2020)... (PRWEB) , ... February 03, 2020 , ... ... Travel, Financial Services Firm Travel, Law Firm Travel, Technology Industry Travel and Biotech/Healthcare ... findings, listed quarterly. Each Index illustrates the following statistics:, ...
(Date:1/28/2020)... ... January 28, 2020 , ... Today, Salimetrics announced an addition ... Salivary Total Human IgG Assay Kit exemplifies Salimetrics’ 20+ year commitment ... can extend the accuracy and ease of use of salivary bioscience into infectious ...
(Date:1/24/2020)... ... January 24, 2020 , ... The impact of new ... therapeutics, laboratory and clinical services during the first two decades of the 21st ... as Slone Partners celebrates its 20th anniversary this year, its evolution ...
Breaking Biology Technology:
Cached News: